Literature DB >> 15066469

Effect of gonadotropin-releasing hormone hypogonadism on insulin action as assessed by hyperglycemic clamp studies in men.

Subodhsingh Chauhan1, Karen Collins, Michael Kruger, Michael P Diamond.   

Abstract

OBJECTIVE: To investigate the effects of decreasing androgen levels on insulin action, in view of the relationship between hyperandrogenism and impaired insulin action in women with polycystic ovary syndrome.
DESIGN: Prospective, clinical study.
SETTING: University hospital. PATIENT(S): Ten normal healthy men. INTERVENTION(S): Gonadotropin-releasing hormone (GnRH) agonist, 3.75 mg, administered monthly for 3 months. MAIN OUTCOME MEASURE(S): Insulin action (M/I ratio). RESULT(S): The M/I ratio decreased from 0.24 +/- 0.04 to 0.17 +/- 0.04 after GnRH agonist therapy. CONCLUSION(S): In normal men, administration of a GnRH analogue was associated with a decrease in both testosterone levels and insulin action.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15066469     DOI: 10.1016/j.fertnstert.2003.08.052

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  3 in total

1.  LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer.

Authors:  Andreza Vargas; Roberto Dias Machado; Daniel Ianni Filho; Carlos Eduardo Paiva; Rodolfo Borges Dos Reis; Marcos Tobias-Machado; Eliney Ferreira Faria
Journal:  World J Urol       Date:  2016-04-21       Impact factor: 4.226

2.  Evaluation of insulin sensitivity in patients with Klinefelter's syndrome: a hyperinsulinemic euglycemic clamp study.

Authors:  Zeki Yesilova; Cagatay Oktenli; S Yavuz Sanisoglu; Ugur Musabak; Erdinc Cakir; Metin Ozata; Kemal Dagalp
Journal:  Endocrine       Date:  2005-06       Impact factor: 3.633

3.  Effect of ovarian suppression with gonadotropin-releasing hormone agonist on glucose disposal and insulin secretion.

Authors:  Michael J Toth; Brian C Cooper; Richard E Pratley; Andrea Mari; Dwight E Matthews; Peter R Casson
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-04-15       Impact factor: 4.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.